Journal
VACCINES
Volume 9, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9111363
Keywords
cancer immunotherapy; adoptive cell therapy; cancer vaccines; dendritic cells; tumor antigens; NK cells; NKG2D; cell-mediated immunity
Categories
Ask authors/readers for more resources
In the past decade, significant progress has been made in adoptive cell therapy, with dendritic cell vaccines and NK cells being potential cell preparations for cancer treatment. While NK cell immunotherapy shows high efficacy and promise against many types of cancer, there are still challenges to be overcome, such as infiltration limitations and low cytotoxic activity in solid tumors.
In the last decade, an impressive advance was achieved in adoptive cell therapy (ACT), which has improved therapeutic potential and significant value in promising cancer treatment for patients. The ACT is based on the cell transfer of dendritic cells (DCs) and/or immune effector cells. DCs are often used as vaccine carriers or antigen-presenting cells (APCs) to prime naive T cells ex vivo or in vivo. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are used as major tool effector cells for ACT. Despite the fact that NK cell immunotherapy is highly effective and promising against many cancer types, there are still some limitations, including insignificant infiltration, adverse conditions of the microenvironment, the immunosuppressive cellular populations, and the low cytotoxic activity in solid tumors. To overcome these difficulties, novel methods of NK cell isolation, expansion, and stimulation of cytotoxic activity should be designed. In this review, we discuss the basic characteristics of DC vaccines and NK cells as potential adoptive cell preparations in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available